For an adult with type 2 diabetes on liraglutide (Victoza) 1.2 mg daily, insulin glargine (Lantus) 20 U and an insulin‑to‑carbohydrate ratio of 1 U per 10 g, with a fasting glucose of approximately 301 mg/dL, how should the basal insulin dose and the insulin‑to‑carbohydrate ratio be adjusted?

Insulin Dose Adjustment for Overnight Hyperglycemia in Type 2 Diabetes

Immediate Basal Insulin Titration

Increase Lantus from 20 units to 24 units immediately (a 4-unit increment), administered at bedtime, because a fasting glucose of 301 mg/dL warrants aggressive basal insulin escalation. 1

• When fasting glucose is ≥180 mg/dL, the American Diabetes Association recommends increasing basal insulin by 4 units every 3 days until fasting glucose reaches the target range of 80–130 mg/dL. 1
• Continue this 4-unit escalation every 3 days as long as fasting glucose remains ≥180 mg/dL, monitoring daily fasting glucose to guide adjustments. 1
• If fasting glucose falls to 140–179 mg/dL during titration, reduce the increment to 2 units every 3 days. 1
• If any unexplained hypoglycemia (glucose <70 mg/dL) occurs, reduce the current Lantus dose by 10–20% immediately before the next administration. 1

Critical Threshold for Basal Insulin Escalation

Stop increasing Lantus when the dose approaches 0.5 units/kg/day (approximately 35–40 units for most adults) without achieving fasting glucose targets; at this threshold, add prandial insulin rather than continuing basal escalation to avoid "over-basalization." 1

• Clinical signals of over-basalization include: basal dose >0.5 units/kg/day, bedtime-to-morning glucose differential ≥50 mg/dL, hypoglycemia episodes despite overall hyperglycemia, and high glucose variability. 1
• When basal insulin exceeds 0.5–1.0 units/kg/day without meeting glycemic goals, adding prandial insulin becomes more appropriate than further basal increases. 1

Insulin-to-Carbohydrate Ratio (ICR) Assessment

The current ICR of 1:10 (1 unit per 10 grams of carbohydrate) is a reasonable starting point and should be maintained initially while focusing on basal insulin optimization. 1

• The ICR should only be adjusted if 2-hour post-prandial glucose values consistently miss target (<180 mg/dL) after at least 3 days of observation at the current ratio. 1
• A fasting glucose of 301 mg/dL indicates inadequate basal coverage, not a problem with the ICR; therefore, prioritize basal insulin titration before modifying the carbohydrate ratio. 1
• If post-prandial glucose remains >180 mg/dL after basal optimization, consider tightening the ICR from 1:10 to 1:8 or adding scheduled prandial insulin doses. 1

Liraglutide (Victoza) Dose Escalation

Continue the planned escalation of Victoza from 1.2 mg to 1.8 mg daily after at least one week at the current dose, as this will provide additional glucose-lowering effect and help address both fasting and post-prandial hyperglycemia. 2, 3

• The starting dose of liraglutide is 0.6 mg daily to improve gastrointestinal tolerability; after at least 1 week, increase to 1.2 mg, and some patients benefit from a further increment to the maximum recommended dose of 1.8 mg. 2
• Liraglutide increases insulin production in a glucose-dependent manner and has a low incidence of hypoglycemia when used with basal insulin. 2, 3
• The combination of basal insulin plus a GLP-1 receptor agonist like liraglutide provides potent glucose-lowering with less weight gain and hypoglycemia risk compared with basal-bolus insulin regimens. 4

Monitoring Requirements During Titration

Check fasting glucose daily during the titration phase to guide Lantus dose adjustments, aiming for a target range of 80–130 mg/dL. 1

• Measure pre-meal glucose before each meal to calculate any needed correction doses. 1
• Obtain 2-hour post-prandial glucose readings after meals to assess the adequacy of the ICR and determine if prandial insulin is needed. 1
• Reassess the insulin regimen every 3 days during active titration. 1
• Check HbA1c every 3 months until stable control is achieved. 1

Foundation Therapy Optimization

Continue metformin at the maximum tolerated dose (up to 2,000–2,550 mg daily) when intensifying insulin therapy, as this combination reduces total insulin requirements by 20–30% and provides superior glycemic control. 1

• Metformin should not be discontinued when adding or intensifying insulin unless specific contraindications exist (e.g., renal impairment, acute illness). 1
• The combination of metformin with basal insulin and a GLP-1 RA yields the best outcomes for glucose control and weight management. 1

When to Add Prandial Insulin

If basal insulin reaches approximately 0.5 units/kg/day (35–40 units) without achieving fasting glucose targets, or if HbA1c remains above goal after 3–6 months despite optimized basal insulin, add prandial insulin coverage. 1

• Start with 4 units of rapid-acting insulin (lispro, aspart, or glulisine) before the largest meal, or use 10% of the current basal dose as the initial prandial amount. 1
• Administer prandial insulin 0–15 minutes before meals for optimal post-prandial control. 1
• Titrate each meal dose by 1–2 units every 3 days based on 2-hour post-prandial glucose readings, targeting <180 mg/dL. 1

Hypoglycemia Management

Treat any glucose <70 mg/dL immediately with 15 grams of fast-acting carbohydrate, recheck in 15 minutes, and repeat if needed. 1

• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20% before the next administration. 1
• Never use rapid-acting insulin at bedtime as a sole correction dose, as this markedly raises nocturnal hypoglycemia risk. 1

Common Pitfalls to Avoid

• Do not delay aggressive basal insulin titration when fasting glucose consistently exceeds 180 mg/dL; prolonged hyperglycemia increases complication risk. 1
• Do not continue escalating Lantus beyond 0.5–1.0 units/kg/day without addressing post-prandial hyperglycemia, as this leads to over-basalization with increased hypoglycemia risk and suboptimal control. 1
• Do not adjust the ICR based on a single fasting glucose reading; the current overnight hyperglycemia reflects inadequate basal insulin, not a problem with carbohydrate coverage. 1
• Do not rely solely on correction insulin without adjusting scheduled basal doses; correction doses must supplement, not replace, scheduled insulin. 1

Expected Clinical Outcomes

• With aggressive basal insulin titration (4-unit increments every 3 days for fasting glucose ≥180 mg/dL), fasting glucose should fall to 80–130 mg/dL within 2–3 weeks. 1
• The combination of optimized basal insulin, liraglutide 1.8 mg daily, and metformin can produce HbA1c reductions of 2–3% over 3–6 months. 1, 3
• Properly implemented basal insulin titration does not increase hypoglycemia risk when doses are adjusted systematically based on glucose patterns. 1